{
    "organizations": [],
    "uuid": "ede50f22a7aea45f7df7900de91f42e51e2b49dd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-respiratorius-presents-positive-re/brief-respiratorius-presents-positive-results-from-clinical-studies-of-val001-idUSFWN1QI0EH",
    "ord_in_thread": 0,
    "title": "BRIEF-Respiratorius Presents Positive Results From Clinical Studies Of VAL001",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - RESPIRATORIUS AB (PUBL):\n* RESPIRATORIUS PRESENTS POSITIVE RESULTS FROM CLINICAL STUDIES OF VAL001\n* ‍PUBLISHED SCIENTIFIC RESULTS FROM PHASE I STUDY SHOW A POTENTIAL SYNERGISTIC EFFECT WITH RITUXIMAB AS VAL001 INCREASES LEVELS OF SURFACE PROTEIN CD20​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-28T15:30:00.000+02:00",
    "crawled": "2018-03-01T21:10:15.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "respiratorius",
        "ab",
        "publ",
        "respiratorius",
        "present",
        "positive",
        "result",
        "clinical",
        "study",
        "val001",
        "scientific",
        "result",
        "phase",
        "study",
        "show",
        "potential",
        "synergistic",
        "effect",
        "rituximab",
        "val001",
        "increase",
        "level",
        "surface",
        "protein",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}